

# Jean-Philippe COLLET France

Application for the following position in the EAPCI Board:
TREASURER

Member of EAPCI.

### **Profession**

X	Inte	rven	tion	alist
^	1111		CIOII	unst

	Haalthcara	Drofoccional	Murca	Dadiograph	her, Technicia	a) workina i	n DCI
ш	ricaltitale	1 101633101141	(INUISE,	Radiograp	nei, recinnicia	I) WOLKING I	11 1 C1

- ☐ Industry Professional
- □ Other

### **Additional Information**

- x Fellow of the ESC
- x EAPCI Member





- x Member of another ESC Association (beyond EAPCI)

  If yes, specify: Working Group on Thrombosis. CPG Committee.
- ☐ Active in an ESC Member Country

If yes, specify your country of work:

- Member of a National Cardiac Society
   If yes, specify: SFC (Société Française de Cardiologie)
- x Member of an Interventional Working Group If yes, specify: GACI (French Group of Interventional Cardiology)

### General CV (as it pertains to PCI) - 300 words max

### Jean-Philippe COLLET MD, PhD

- Institut de Cardiologie-UMRS 166- Hôpital de la Pitié-Salpêtrière-75013 Paris

Phone: 00 331 42162962Fax: 00 331 42162931

E-mail: jean-philippe.collet@psl.aphp.fr

### **Administrative and Academic Appointments**

#### Director of the Interventional Catheterization Laboratory

- Interventional Cardiologist at the Institut de Cardiologie
- Hôpital de la Pitié-Salpêtrière, Université Pierre et Marie Curie

### Director of the Cardiovascular Training Program at the Université Pierre et Marie Curie

- Professor of Cardiology at Université Pierre et Marie Curie (Paris 6)
- Co-director of the INSERM 1166, UPMC, Paris 75013

### <u>Director of the Research Unit on Thrombosis, Atherothrombosis and Applied Pharmacology</u>

- Five full time persons
- Main research objectives:
  - New models for experimental thrombosis
  - Demonstration of the prognostic role of biomarkers
  - Comparative evaluation of antithrombotic therapies
  - Reassessment of antithrombotic drug regimens (PK and PD models for drug evaluation)
  - Phase 1 study for oral antithrombotic treatment
  - Core laboratory for angiography and biology





Randomized trials (<u>www.action-coeur.org</u>).

### Certifications and Scientific Societies

- Specialist in cardiology (MD), Université Paris XII
- PhD in Thrombosis, University of Rouen, France
- Member of the French Society of Cardiology
- Member of the European Society of Cardiology (FESC)
- Nucleus Member of the Working Group 18 (Thrombosis)
- Member of EAPCI
- Member of the Clinical Practice Guidelines Committee

### **Research Activities**

Dr Jean-Philippe Collet is a Professor of Cardiology at Pitié-Salpêtrière University Hospital in Paris where he leads the interventional catheterization unit (PCI and TAVI). His main expertise is in the field of thrombosis, the effect of antithrombotic agents and the development of new devices for structural heart intervention. He has been a pioneer in the field of thrombus structural properties but also in the pharmacogenetic of clopidogrel treatment and platelet function testing. He is a member and a founder of the Academic Research Organisation A.C.T.I.O.N (Alliés in Cardiovascular Trials, Initiatives and Organized Networks) (www.action-coeur.org). He has led clinical trials as a principal investigator (AMERIC A, DOSAPI, ARCTIC and ATLANTIS). He has several commitments in the ESC. He is a Fellow of the European Society of Cardiology, a member of the nucleus of the WG Thrombosis and a member of the Clinical Practice Guidelines Committee. He is serving as an expert in several ESC guidelines. He has served as the Chair of the EAPCI scientific program for two years (2014-2016).

### **Publications**

Articles: 420Book chapters: 45Abstracts: 200H-index=47

### Previous experience in EAPCI, ESC or your National Bodies

Specifically, please indicate if you hold an Executive position (President, Vice President, President Elect) in a National Cardiac Society or in the ESC. If so, please indicate which one as well as the term of this position.

NONE





### If you have been involved in EAPCI in the past, please specify the position(s) as well as the relevant date(s)

In particular, please indicate if you served in:

•	EAPCI Board 2016-2018 (under M. Haude's leadership)?	Yes
•	EAPCI Board 2014-2016 (under S. Windecker's leadership)?	Yes
•	EAPCI Board 2011-2014 (under J. Fajadet's leadership)?	No
•	EAPCI Board 2009-2011 (under C. Di Mario's leadership)?	No
•	EAPCI Board 2006-2009 (under W. Wijns' leadership)?	No

If you answered yes to at least one of these questions, please provide details.

Chair of the Scientific Program Committee for two years.

### Publications in the field of PCI (most important 10 publications)

- 1. <u>Collet JP</u>, Roffi M, Byrne RA, Costa F, Valgimigli M; Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC); ESC Scientific Document Group; Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC). Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease: The Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). <u>Eur Heart J. 2017</u> Aug 26. doi: 10.1093/eurheartj/ehx503
- 2. Auffret V, Lefevre T, Van Belle E, Eltchaninoff H, Iung B, Koning R, Motreff P, Leprince P, Verhoye JP, Manigold T, Souteyrand G, Boulmier D, Joly P, Pinaud F, Himbert D, Collet JP, Rioufol G, Ghostine S, Bar O, Dibie A, Champagnac D, Leroux L, Collet F, Teiger E, Darremont O, Folliguet T, Leclercq F, Lhermusier T, Olhmann P, Huret B, Lorgis L, Drogoul L, Bertrand B, Spaulding C, Quilliet L, Cuisset T, Delomez M, Beygui F, Claudel JP, Hepp A, Jegou A, Gommeaux A, Mirode A, Christiaens L, Christophe C, Cassat C, Metz D, Mangin L, Isaaz K, Jacquemin L, Guyon P, Pouillot C, Makowski S, Bataille V, Rodés-Cabau J, Gilard M, Le Breton H; FRANCE TAVI Investigators. Temporal Trends in Transcatheter Aortic Valve Replacement in France: FRANCE 2 to FRANCE TAVI. J Am Coll Cardiol. 2017 Jul 4;70(1):42-55.
- 3. Gerardin B, <u>Collet JP</u>, Mustafic H, Bellemain-Appaix A, Benamer H, Monsegu J, Teiger E, Livarek B, Jaffry M, Lamhaut L, Fleischel C, Aubry P; Groupe de Réflexion sur la Cardiologie Interventionnelle. Registry on acute cardiovascular events during endurance running races: the prospective RACE Paris registry. <u>Eur Heart J. 2016</u> Aug 21;37(32):2531-41.
- 4. Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, Delarche N, Bellemain-Appaix A, Range G, El Mahmoud R, Carrié D, Belle L, Souteyrand G, Aubry P, Sabouret P, du Fretay XH, Beygui F, Bonnet JL, Lattuca B, Pouillot C, Varenne O, Boueri Z, Van Belle E, Henry P, Motreff P, Elhadad S, Salem JE, Abtan J, Rousseau H, Collet JP, Vicaut E, Montalescot G; ANTARCTIC investigators. Platelet





function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. **Lancet. 2016** Oct 22;388(10055):2015-2022.

- 5. Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Stibbe O, Ecollan P, Heutz WM, Swahn E, <u>Collet JP</u>, Willems FF, Baradat C, Licour M, Tsatsaris A, Vicaut E, Hamm CW; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. <u>N</u> <u>Engl J Med. 2014</u> Sep 11;371(11):1016-2.
- 6. <u>Collet JP</u>, Silvain J, Barthélémy O, Rangé G, Cayla G, Van Belle E, Cuisset T, Elhadad S, Schiele F, Lhoest N, Ohlmann P, Carrié D, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, Montalescot G; for the ARCTIC investigators. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. <u>Lancet 2014</u> 6736(14): 60612-7.
- 7. Montalescot G, Rangé G, Silvain J, Bonnet JL, Boueri Z, Barthélémy O, Cayla G, Belle L, Van Belle E, Cuisset T, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, <u>Collet JP</u>; ARCTIC Investigators. High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study. <u>Circulation</u>. 2014 May 27;129(21):2136-43.
- 8. <u>Collet JP</u>, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthélémy O, Beygui F, Silvain J, M D EV, Montalescot G; the ARCTIC Investigators. Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. <u>N Engl J Med. 2012</u>; 367(22):2100-9
- 9. Cayla G, Hulot J-S, O'Connor SA, Pathak A, Scott SA, Gruel Y, Silvain J, Vignalou J-B, Huerre Y, de la Briolle A, Allanic F, Beygui F, Barthélémy O, Montalescot G, <u>Collet J-P</u>. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. <u>JAMA</u>. 2011; 306:1765–1774.
- 10. <u>Collet JP</u>, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. <u>Lancet</u>. 2009;373(9660):309-17.

### What would you like to achieve if you were elected?

The best for EAPCI that is to have more affiliates, to promote our discipline that is evolving very fast especially with technological advances in structural heart interventions. Another important achievement would be education of the young fellows with recognition of a European certification label at the level of each National Society. Finally, promoting specific structural heart interventions guidelines would be another great achievement that I would be supportive of.





## If you were elected, how do you envisage to organize yourself to accommodate this very demanding additional commitment?

I am used to travel for ESC short trip and teleconference. I know few members of the EAPCI board and have a similar organization. I should be able to make it.

